Retroviral Integrations in Gene Therapy Trials

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2012 Jan 19

PMID 22252453

Citations 55

Authors

Luca Biasco

Cristina Baricordi

Alessandro Aiuti

Affiliations

Soon will be listed here.

Abstract

γ-Retroviral and lentiviral vectors allow the permanent integration of a therapeutic transgene in target cells and have provided in the last decade a delivery platform for several successful gene therapy (GT) clinical approaches. However, the occurrence of adverse events due to insertional mutagenesis in GT treated patients poses a strong challenge to the scientific community to identify the mechanisms at the basis of vector-driven genotoxicity. Along the last decade, the study of retroviral integration sites became a fundamental tool to monitor vector-host interaction in patients overtime. This review is aimed at critically revising the data derived from insertional profiling, with a particular focus on the evidences collected from GT clinical trials. We discuss the controversies and open issues associated to the interpretation of integration site analysis during patient's follow up, with an update on the latest results derived from the use of high-throughput technologies. Finally, we provide a perspective on the future technical development and on the application of these studies to address broader biological questions, from basic virology to human hematopoiesis.

Citing Articles

Efficient Dual Cas9 Nickase Correction of a Prevalent Pathogenic Variant for Junctional Epidermolysis Bullosa.

du Rand A, Hunt J, Verdon D, Buttle B, Dunbar P, Purvis D JID Innov. 2025; 5(3):100343.

PMID: 39944129 PMC: 11815943. DOI: 10.1016/j.xjidi.2024.100343.

Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.

Bischof J, Hierl M, Koller U Int J Mol Sci. 2024; 25(4).

PMID: 38396920 PMC: 10889532. DOI: 10.3390/ijms25042243.

Tagmentation-based analysis reveals the clonal behavior of CAR-T cells in association with lentivector integration sites.

Kim J, Park M, Baek G, Kim J, Kwon E, Kang B Mol Ther Oncolytics. 2023; 30:1-13.

PMID: 37360944 PMC: 10285042. DOI: 10.1016/j.omto.2023.05.004.

mRNA Transfection of T-Lymphocytes by Electroporation.

Schwarze L, Fehse B Methods Mol Biol. 2021; 2285:217-226.

PMID: 33928556 DOI: 10.1007/978-1-0716-1311-5_18.

Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells.

Lenogue K, Walencik A, Laulagnier K, Molens J, Benlalam H, Dreno B Vaccines (Basel). 2021; 9(2).

PMID: 33578850 PMC: 7916617. DOI: 10.3390/vaccines9020141.

References

Kustikova O, Geiger H, Li Z, Brugman M, Chambers S, Shaw C . Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood. 2006; 109(5):1897-907. PMC: 1801061. DOI: 10.1182/blood-2006-08-044156. View

Brady T, Agosto L, Malani N, Berry C, ODoherty U, Bushman F . HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS. 2009; 23(12):1461-71. PMC: 2862484. DOI: 10.1097/QAD.0b013e32832caf28. View

Avedillo Diez I, Zychlinski D, Coci E, Galla M, Modlich U, Dewey R . Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm. 2011; 8(5):1525-37. DOI: 10.1021/mp200132u. View

Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B . Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood. 2007; 110(6):1770-8. DOI: 10.1182/blood-2007-01-068759. View

Cavazzana-Calvo M, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288(5466):669-72. DOI: 10.1126/science.288.5466.669. View

Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack M, Wulffraat N, Leboulch P . LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302(5644):415-9. DOI: 10.1126/science.1088547. View

Ginn S, Liao S, Dane A, Hu M, Hyman J, Finnie J . Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther. 2010; 18(5):965-76. PMC: 2890120. DOI: 10.1038/mt.2010.50. View

Urnov F, Miller J, Lee Y, Beausejour C, Rock J, Augustus S . Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005; 435(7042):646-51. DOI: 10.1038/nature03556. View

Recchia A, Bonini C, Magnani Z, Urbinati F, Sartori D, Muraro S . Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A. 2006; 103(5):1457-62. PMC: 1360534. DOI: 10.1073/pnas.0507496103. View

10.

Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M . LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J Virol. 2004; 78(17):9524-37. PMC: 506940. DOI: 10.1128/JVI.78.17.9524-9537.2004. View

11.

de Ridder J, Uren A, Kool J, Reinders M, Wessels L . Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol. 2006; 2(12):e166. PMC: 1676030. DOI: 10.1371/journal.pcbi.0020166. View

12.

Ikeda K, Mason P, Bessler M . 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood. 2011; 117(22):5860-9. PMC: 3112035. DOI: 10.1182/blood-2011-02-334425. View

13.

Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-42. PMC: 2496963. DOI: 10.1172/JCI35700. View

14.

Bester A, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M . Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther. 2006; 13(13):1057-9. DOI: 10.1038/sj.gt.3302752. View

15.

Gerrits A, Dykstra B, Kalmykowa O, Klauke K, Verovskaya E, Broekhuis M . Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood. 2010; 115(13):2610-8. DOI: 10.1182/blood-2009-06-229757. View

16.

Shimizu S, Nagasawa T, Katoh O, Komatsu N, Yokota J, Morishita K . EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem Biophys Res Commun. 2002; 292(3):609-16. DOI: 10.1006/bbrc.2002.6693. View

17.

Seger R . Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med. 2010; 68(11):334-40. View

18.

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

19.

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

20.

Kang E, Choi U, Theobald N, Linton G, Long Priel D, Kuhns D . Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2009; 115(4):783-91. PMC: 2815517. DOI: 10.1182/blood-2009-05-222760. View